# Anti-angiogenesis in human lymphomas. New insights

## TL;DR

This paper reviews recent developments in using anti-angiogenic treatments for human lymphomas and suggests combining therapies to improve effectiveness.

## Contribution

The paper highlights new therapeutic strategies to overcome resistance in anti-angiogenic treatment of lymphomas.

## Key findings

- Anti-angiogenic monotherapy alone may not be effective for treating lymphomas.
- Combining anti-angiogenic agents with other treatments could enhance therapeutic outcomes.
- Alternative strategies are needed to address resistance in anti-angiogenic therapy.

## Abstract

Targeting tumor angiogenesis is an advancement in the treatment of hematological malignancies. This article summarizes the most recent advancements in the use of anti-angiogenic agents in the treatment of human lymphomas. Preclinical and clinical studies have evidenced that treating lymphomas with anti-angiogenic monotherapy may not be successful. Alternative therapeutic strategies may be used to overcome resistance to anti-angiogenic therapy, including the association of different anti-angiogenic molecules or their combination with other treatment regimens.